Urs Rohner - GSK Plc Non-Executive Independent Director
| GLAXF Stock | USD 20.20 0.13 0.65% |
Director
Mr. Urs Rohner is NonExecutive Independent Director of GlaxoSmithKline PLC. Urs has a broad range of business and legal experience having served as Chairman on a number of Boards, most recently for Credit Suisse, a worldleading financial services company. Prior to joining Credit Suisse in 2004, Urs served as Chairman of the Executive Board and CEO of ProSieben and ProSiebenSat.1 Media AG. This followed a number of years in private practice at major law firms in Switzerland and the US, having been admitted to the bars of the canton of Zurich in Switzerland in 1986 and the state of New York in the US in 1990. Urs is Chairman of the Board of Credit Suisse Group AG and of its Chairmans and Governance Committee. He is also Chairman and member of the Board of Trustees of Credit Suisse Research Institute and Credit Suisse Foundation. Urs was appointed ViceChairman of the Governing Board of the Swiss Bankers Association in 2015. since 2015.
| Age | 59 |
| Tenure | 9 years |
| Phone | 44 20 8047 5000 |
| Web | https://www.gsk.com |
GSK Plc Management Efficiency
The company has return on total asset (ROA) of 0.0659 % which means that it generated a profit of $0.0659 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3131 %, meaning that it generated $0.3131 on every $100 dollars invested by stockholders. GSK Plc's management efficiency ratios could be used to measure how well GSK Plc manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Diane Souza | Sanofi ADR | 65 | |
| Cornelia Bargmann | AstraZeneca PLC | N/A | |
| Dennis Ausiello | Pfizer Inc | 71 | |
| Laurie Glimcher | Bristol Myers Squibb | 64 | |
| Elizabeth Doherty | Novartis AG | 61 | |
| Makoto Takeuchi | Astellas Pharma | N/A | |
| Nuria Lapena | Grifols SA ADR | N/A | |
| Marc Dunoyer | AstraZeneca PLC | 71 | |
| Akihiro Okumura | Santen Pharmaceutical Co | 70 | |
| Yuichi Murakami | Astellas Pharma | N/A | |
| Thomas Suedhof | Sanofi ADR | 62 | |
| Graham Chipchase | AstraZeneca PLC | 54 | |
| Michael Bonney | Bristol Myers Squibb | 61 | |
| Anita Hauser | Roche Holding AG | 49 | |
| Christoph Franz | Roche Holding Ltd | 58 | |
| Srikant Datar | Novartis AG | 64 | |
| Christoph Franz | Roche Holding AG | 58 | |
| Claudia Dyckerhoff | Roche Holding Ltd | 51 | |
| Wyllie Cornwell | Pfizer Inc | 71 | |
| Carina Lazaro | Grifols SA ADR | 48 | |
| Deborah DiSanzo | AstraZeneca PLC | 58 | |
Management Performance
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 |
GSK plc Leadership Team
Elected by the shareholders, the GSK Plc's board of directors comprises two types of representatives: GSK Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GSK. The board's role is to monitor GSK Plc's management team and ensure that shareholders' interests are well served. GSK Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GSK Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vindi Banga, Senior Independent Non-Executive Director | ||
| Lynn Elsenhans, Independent Non-Executive Director | ||
| Luke Miels, President - Global Pharmaceuticals | ||
| Hal Barron, Chief Scientific Officer and Presidentident - R&D, Executive Director | ||
| Daniel Podolsky, Non-Executive Independent Director | ||
| Emma Walmsley, President - Consumer Healthcare Worldwide | ||
| Luc Debruyne, President - Global Vaccines | ||
| Andrew Witty, CEO, Executive Director | ||
| Brian McNamara, CEO - GSK Consumer Healthcare | ||
| Roy Anderson, Non-Executive Independent Director | ||
| Philip Hampton, Independent Non-Executive Director | ||
| Simon Dingemans, CFO, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee | ||
| Vivienne Cox, Non-Executive Director | ||
| Bill Louv, Senior Vice President - Core Business Services | ||
| Diana Conrad, Chief Officer | ||
| Roger Connor, President - Global Manufacturing & Supply | ||
| Abbas Hussain, President Global Pharmaceuticals | ||
| Phil Thomson, Senior Vice President - Global Communications | ||
| Judy Lewent, Non-Executive Independent Director | ||
| Hans Wijers, Independent Non-Executive Director | ||
| Shobie Ramakrishnan, Chief Officer | ||
| Sarah EltonFarr, Head Relations | ||
| Stephanie Burns, Non-Executive Independent Director | ||
| Julie Brown, Chief Officer | ||
| Moncef Slaoui, Chairman of Global Vaccines, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee | ||
| Urs Rohner, Non-Executive Independent Director | ||
| Marvinder Banga, Senior Non-Executive Independent Director | ||
| Deryck Maughan, Senior Independent Non-Executive Director | ||
| Jesse Goodman, Non-Executive Director | ||
| Laurie Glimcher, Non-Executive Director | ||
| Nick Hirons, Senior Vice President - Global Ethics and Compliance | ||
| Sally Jackson, VP Office | ||
| James Ford, Senior Vice President General Counsel | ||
| Victoria Whyte, Company Secretary | ||
| Daniel Troy, Sr. VP and General Counsel | ||
| Shah Hussain, President - Europe, Japan & EMAP | ||
| Tony Wood, Chief Officer | ||
| Manvinder Banga, Non-Executive Director | ||
| David Redfern, Chief Strategy Officer | ||
| Patrick Vallance, President - Pharmaceuticals R&D | ||
| Stacey Cartwright, Non-Executive Independent Director | ||
| Regis Simard, President - Pharmaceutical Supply Chain | ||
| Iain Mackay, CFO - Designate, Executive Director | ||
| Karenann Terrell, Chief Digital & Technology Officer | ||
| Claire Thomas, Senior Vice President - Human Resources |
GSK Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is GSK Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 | |||
| Profit Margin | 0.51 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 90.86 B | |||
| Shares Outstanding | 4.09 B | |||
| Shares Owned By Insiders | 0.60 % | |||
| Shares Owned By Institutions | 41.06 % | |||
| Price To Earning | 11.44 X | |||
| Price To Book | 6.49 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards GSK Plc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, GSK Plc's short interest history, or implied volatility extrapolated from GSK Plc options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GSK plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for GSK Pink Sheet analysis
When running GSK Plc's price analysis, check to measure GSK Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GSK Plc is operating at the current time. Most of GSK Plc's value examination focuses on studying past and present price action to predict the probability of GSK Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GSK Plc's price. Additionally, you may evaluate how the addition of GSK Plc to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |